To determine appropriate treatment doses of cold atmospheric plasma (CAP), the Canady Helios Cold Plasma Scalpel was tested across numerous cancer cell types including renal adenocarcinoma, colorectal carcinoma, pancreatic adenocarcinoma, ovarian adenocarcinoma, and esophageal adenocarcinoma. Various CAP doses were tested consisting of both high (3 L/min) and low (1 L/min) helium flow rates, several power settings, and a range of treatment times up to 5 min. The impact of cold plasma on the reduction of viability was consistently dose-dependent; however, the anti-cancer capability varied significantly between cell lines. While the lowest effective dose varied from cell line to cell line, in each case an 80–99% reduction in viability was achievable 48 h after CAP treatment. Therefore, it is critical to select the appropriate CAP dose necessary for treating a specific cancer cell type.

Triple-negative breast cancer is a phenotype of breast cancer where the expression level of estrogen, progesterone and human epidermal growth factor receptor 2 (HER2) receptors are low or absent. It is more frequently diagnosed in younger and premenopausal women, among which African and Hispanic have a higher rate. Cold atmospheric plasma has revealed its promising ant-cancer capacity over the past two decades. In this study, we report the first cold plasma jet delivered by the Canady Cold Plasma Conversion Unit and characterization of its electric and thermal parameters. The unit effectively reduced the viability of triple-negative breast cancer up to 80% without thermal damage, providing a starting point for future clinical trials.

The use of plasma energy has expanded in surgery and medicine. Tumor resection in surgery and endoscopy has incorporated the use of a plasma scalpel or catheter for over four decades. A new plasma energy has expanded the tools in surgery: Cold Atmospheric Plasma (CAP). A cold plasma generator and handpiece are required to deliver the CAP energy. The authors evaluated a new Cold Plasma Jet System. The Cold Plasma Jet System consists of a USMI Cold Plasma Conversion Unit, Canady Helios Cold Plasma^® Scalpel, and the Canady Plasma^® Scalpel in Hybrid and Argon Plasma Coagulation (APC) modes. This plasma surgical system is designed to remove the target tumor with minimal blood loss and subsequently spray the local area with cold plasma. In this study, various operational parameters of the Canady Plasma^® Scalpels were tested on ex vivo normal porcine liver tissue. These conditions included various gas flow rates (1.0, 3.0, 5.0 L/min), powers (20, 40, 60 P), and treatment durations (30, 60, 90, 120 s) with argon and helium gases. Plasma length, tissue temperature changes, and depth and eschar injury magnitude measurements resulting from treatment were taken into consideration in the comparison of the scalpels. The authors report that a new cold plasma jet technology does not produce any thermal damage to normal tissue.